Journal
LEUKEMIA
Volume 32, Issue 5, Pages 1200-1210Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/s41375-018-0019-y
Keywords
-
Categories
Funding
- Associazione Italiana per la Ricerca sul Cancro (AIRC
- Milan, Italy), Special Program Molecular Clinical Oncology 5 x 1000 [1005]
- Progetto Ministero della Salute [GR-2011-02352109]
- Fondazione Matarelli, (Milano)
- Fondazione Rusconi (Varese)
- AIL (Varese)
- Henry J. Predolin foundation grant (Madison, WI, USA)
Ask authors/readers for more resources
A total of 410 patients with blast phase myeloproliferative neoplasm (MPN-BP) were retrospectively reviewed: 248 from the Mayo Clinic and 162 from Italy. Median survival was 3.6 months, with no improvement over the last 15 years. Multivariable analysis performed on the Mayo cohort identified high risk karyotype, platelet count < 100 x 10(9)/L, age > 65 years and transfusion need as independent risk factors for survival. Also in the Mayo cohort, intensive chemotherapy resulted in complete remission (CR) or CR with incomplete count recovery (CRi) rates of 35 and 24%, respectively; treatment-specified 3-year/5-year survival rates were 32/10% for patients receiving allogeneic stem cell transplant (AlloSCT) (n = 2 4), 19/13% for patients achieving CR/CRi but were not transplanted (n = 24), and 1/1% in the absence of both AlloSCT and CR/CRi (n = 200) (p < 0.01). The survival impact of AlloSCT (HR 0.2, 95% CI 0.1-0.3), CR/CRi without AlloSCT (HR 0.3, 95% CI 0.2-0.5), high risk karyotype (HR 1.6, 95% CI 1.1-2.2) and platelet count < 100 x 10(9)/L (HR 1.6, 95% CI 1.1-2.2) were confirmed to be inter independent. Similar observations were made in the Italian cohort. The current study identifies the setting for improved short-term survival in MPN-BP, but also highlights the limited value of current therapy, including AlloSCT, in securing long-term survival.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available